LPCN - Lipocine Inc. - SEC Form 4 Insider Trading Screener
6 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2017-12-29 | LPCN | Bass Gregory Brooks | Chief Commercial Officer | S - Sale+OE | $3.47 | -3,750 | 5,625 | -40% | -$13,023 | |||||
| D | 2017-12-29 | LPCN | Patel Mahesh V. | CEO, Pres | S - Sale+OE | $3.48 | -6,000 | 722,112 | -1% | -$20,867 | |||||
| D | 2017-12-29 | LPCN | Brown Morgan R | EVP, CFO | S - Sale+OE | $3.47 | -2,813 | 23,562 | -11% | -$9,773 | |||||
| D | 2017-12-29 | LPCN | Hill Stephen A | Dir | S - Sale+OE | $3.47 | -1,250 | 5,250 | -19% | -$4,342 | |||||
| D | 2017-12-29 | LPCN | Ono Richard Dana | Dir | S - Sale+OE | $3.47 | -875 | 4,875 | -15% | -$3,033 | |||||
| D | 2017-12-29 | LPCN | Fink Jeffrey Arvin | Dir | S - Sale+OE | $3.47 | -938 | 937 | -50% | -$3,258 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |